Literature DB >> 22516069

Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis.

Pia R Kamstrup1, Anne Tybjærg-Hansen, Børge G Nordestgaard.   

Abstract

OBJECTIVE: The aim of the present study was to determine whether lipoprotein(a) [Lp(a)], considered a causal risk factor for cardiovascular disease, primarily promotes thrombosis or atherosclerosis. METHODS AND
RESULTS: Using a Mendelian randomization study design, we measured plasma Lp(a) and genetically elevated Lp(a) levels through the LPA kringle IV type 2 repeat genotype in 41231 individuals. We included 2 general population studies of both venous thrombosis and combined thrombosis and atherosclerosis in coronary arteries (=myocardial infarction), and 3 -case--control studies of atherosclerotic stenosis. Neither Lp(a) tertiles nor LPA kringle IV type 2 tertiles associated with the risk of venous thrombosis in general population studies (trend: P=0.12-0.76), but did each associate with risk of coronary, carotid, and femoral atherosclerotic stenosis in -case--control studies (trend: P<0.001 to 0.04). Lp(a) and LPA kringle IV type 2 tertiles also associated with the risk of myocardial infarction in general population studies (trend: P<0.001 to 0.003). For doubling of Lp(a) levels, instrumental variable estimates of hazard/odds ratios were 1.02 (95% CI 0.90-1.15) and 1.04 (0.93-1.16) for venous thrombosis in the 2 general population studies, 1.12 (1.01-1.25), 1.17 (1.05-1.32), and 1.16 (1.01-1.35), respectively, for coronary, carotid, and femoral atherosclerotic stenosis in -case-control studies, and 1.21 (1.10-1.33) and 1.17 (1.05-1.29) for myocardial infarction in general population studies.
CONCLUSIONS: This supports that Lp(a) primarily promotes atherosclerotic stenosis rather than venous thrombosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22516069     DOI: 10.1161/ATVBAHA.112.248765

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  39 in total

Review 1.  Lipoprotein (a): Coming of Age at Last.

Authors:  Joseph L Witztum; Henry N Ginsberg
Journal:  J Lipid Res       Date:  2016-02-02       Impact factor: 5.922

Review 2.  Update on lipoprotein(a) as a cardiovascular risk factor and mediator.

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2013-10       Impact factor: 5.113

3.  Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis.

Authors:  Michael B Boffa; Tanya T Marar; Calvin Yeang; Nicholas J Viney; Shuting Xia; Joseph L Witztum; Marlys L Koschinsky; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2019-09-24       Impact factor: 5.922

Review 4.  Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches.

Authors:  Teemu J Niiranen; Ramachandran S Vasan
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-04-25

5.  A genome-wide association study on lipoprotein (a) levels and coronary artery disease severity in a Chinese population.

Authors:  Yibin Liu; Hongkun Ma; Qian Zhu; Bin Zhang; Hong Yan; Hanping Li; Jinxiu Meng; Weihua Lai; Liwen Li; Danqing Yu; Shilong Zhong
Journal:  J Lipid Res       Date:  2019-06-11       Impact factor: 5.922

Review 6.  Structure, function, and genetics of lipoprotein (a).

Authors:  Konrad Schmidt; Asma Noureen; Florian Kronenberg; Gerd Utermann
Journal:  J Lipid Res       Date:  2016-04-13       Impact factor: 5.922

Review 7.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

8.  Rhesus monkey (Macaca mulatta) lipoprotein(a) and apolipoprotein(a): high frequency of small size apolipoprotein(a) isoforms.

Authors:  Byambaa Enkhmaa; Adnan Abbuthalha; Erdembileg Anuurad; Wei Zhang; Alice F Tarantal; Lars Berglund
Journal:  J Med Primatol       Date:  2015-02-12       Impact factor: 0.667

9.  Lipoprotein (a) level, apolipoprotein (a) size, and risk of unexplained ischemic stroke in young and middle-aged adults.

Authors:  Azadeh Beheshtian; Sanyog G Shitole; Alan Z Segal; Dana Leifer; Russell P Tracy; Daniel J Rader; Richard B Devereux; Jorge R Kizer
Journal:  Atherosclerosis       Date:  2016-08-20       Impact factor: 5.162

10.  Detrimental effects of niacin/laropiprant on microvascular reactivity and red cell deformability in patients with elevated lipoprotein(a) levels.

Authors:  Gabriele Cioni; Lucia Mannini; Alessandrello Agatina Liotta; Giovanna D'Alessandri; Cinzia Fatini; Brunella Bandinelli; Maria Costanzo; Rosanna Abbate; Rossella Marcucci
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.